Melanoma Variability at Single-Cell Level Predicts Treatment Responses, Say Moffitt Researchers
October 09, 2019
October 09, 2019
TAMPA, Florida, Oct. 9 [TNSmedicalresearch] -- Moffitt Cancer Center issued the following news release:
Patients with advanced melanoma have been able to live longer because of several newly approved targeted treatment options, including BRAF and MEK inhibitors.
However, patients will often have different responses to the same treatment due to genetic variability. Melanoma varies from patient to patient, but genetic variability is also prevalent among different cells f . . .
Patients with advanced melanoma have been able to live longer because of several newly approved targeted treatment options, including BRAF and MEK inhibitors.
However, patients will often have different responses to the same treatment due to genetic variability. Melanoma varies from patient to patient, but genetic variability is also prevalent among different cells f . . .